900 related articles for article (PubMed ID: 18278853)
1. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
[TBL] [Abstract][Full Text] [Related]
2. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2010 Jan; 21(1):151-6. PubMed ID: 20000684
[TBL] [Abstract][Full Text] [Related]
3. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799
[TBL] [Abstract][Full Text] [Related]
4. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
[TBL] [Abstract][Full Text] [Related]
5. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Biotechnol Bioeng; 2011 Jan; 108(1):186-96. PubMed ID: 20803562
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
Hui EK; Boado RJ; Pardridge WM
Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
[TBL] [Abstract][Full Text] [Related]
7. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
[TBL] [Abstract][Full Text] [Related]
8. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
Boado RJ
Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
[TBL] [Abstract][Full Text] [Related]
9. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
10. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
11. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Jun; 100(2):387-96. PubMed ID: 18080333
[TBL] [Abstract][Full Text] [Related]
12. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.
Lehtolainen P; Wirth T; Taskinen AK; Lehenkari P; Leppänen O; Lappalainen M; Pulkkanen K; Marttila A; Marjomäki V; Airenne KJ; Horton M; Kulomaa MS; Ylä-Herttuala S
Gene Ther; 2003 Dec; 10(25):2090-7. PubMed ID: 14595382
[TBL] [Abstract][Full Text] [Related]
13. Functional and pharmacokinetic properties of antibody-avidin fusion proteins.
Shin SU; Wu D; Ramanathan R; Pardridge WM; Morrison SL
J Immunol; 1997 May; 158(10):4797-804. PubMed ID: 9144494
[TBL] [Abstract][Full Text] [Related]
14. Design of a bifunctional fusion protein for ovarian cancer drug delivery: single-chain anti-CA125 core-streptavidin fusion protein.
Wang WW; Das D; McQuarrie SA; Suresh MR
Eur J Pharm Biopharm; 2007 Mar; 65(3):398-405. PubMed ID: 17257818
[TBL] [Abstract][Full Text] [Related]
15. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method.
Halabian R; Roudkenar MH; Esmaeili NS; Masroori N; Roushandeh AM; Najafabadi AJ
Vox Sang; 2009 May; 96(4):309-15. PubMed ID: 19175565
[TBL] [Abstract][Full Text] [Related]
17. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
18. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor.
Rodríguez JA; Helguera G; Daniels TR; Neacato II; López-Valdés HE; Charles AC; Penichet ML
J Control Release; 2007 Dec; 124(1-2):35-42. PubMed ID: 17884229
[TBL] [Abstract][Full Text] [Related]
19. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of a high-affinity chimaeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
Biotechnol Appl Biochem; 2006 Feb; 43(Pt 2):93-101. PubMed ID: 16253117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
